Методичні вказівки для проведення практичних занять і організації самостійної роботи з навчальної дисципліни «Управління нерухомим майном» (для студентів 4 курсу денної і заочної форм навчання напряму підготовки 6.080101 – Геодезія, картографія та землеустрій).

Table S2. Week-4 simeprevir pharmacokinetic parameters after administration in (a) Panels 1–3 and (b) Panel 4. (DOCX 15 kb

Additional file 1: of A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-Îą and ribavirin for chronic hepatitis C virus infection

Results (liver disease evolution) Description of data: Hepatic disease progression was assessed as a secondary objective in this study with optional data collection, and the limited data available are displayed in this additional file. (DOCX 17 kb

SVR4 and SVR12 rates for all patients, patients receiving 12 weeks of treatment, and patients receiving >12 weeks of treatment.

<p>SVR4 and SVR12 rates for all patients, patients receiving 12 weeks of treatment, and patients receiving >12 weeks of treatment.</p

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1) - Fig 4

<p>Forest plot showing the results of the final multivariate logistic regression analyses of factors associated with <b>[A]</b> SVR12 and <b>[B]</b> viral relapse in patients receiving 12 weeks of treatment.</p

Patient baseline demographics and disease characteristics.

<p>Data are n (%) unless otherwise stated. HCV GT1 subtype (Coalesce) is based on the <i>NS5B</i> assay, and if not available on LIPA HCV II or Trugene results.</p

Summary of patients experiencing AEs (on-treatment) during the entire treatment phase, overall and according to treatment group (12- or >12-week treatment).

<p>Summary of patients experiencing AEs (on-treatment) during the entire treatment phase, overall and according to treatment group (12- or >12-week treatment).</p

Listing of most frequently-reported AEs (>15% overall) and all AEs of special interest.

<p>AE, adverse event; GI, gastrointestinal.</p

Patient disposition flow chart.

<p>Patient disposition flow chart.</p

SVR12 among patients with HCV GT4 in the 12-week treatment group.

<p>SVR12 among patients with HCV GT4 in the 12-week treatment group.</p

On-treatment AEs Reported During the Study Period.

<p>On-treatment AEs Reported During the Study Period.</p